<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028894</url>
  </required_header>
  <id_info>
    <org_study_id>23andMe_IPF001</org_study_id>
    <nct_id>NCT05028894</nct_id>
  </id_info>
  <brief_title>23andMe IPF Research Study</brief_title>
  <acronym>IPF</acronym>
  <official_title>23andMe Idiopathic Pulmonary Fibrosis Research Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>23andMe, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>23andMe, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long term goal of this study is to increase genetic understanding of IPF to enable the&#xD;
      development of an effective drug for IPF that can improve the lives of those living with the&#xD;
      condition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will recruit 1,000 people who have been diagnosed with IPF or Hermansky-Pudlak&#xD;
      syndrome (HPS). Eligible participants who consent to participate in 23andMe Research and the&#xD;
      IPF Research Study will receive a 23andMe Health + Ancestry kit at no cost. Participants will&#xD;
      provide a saliva sample and take a baseline survey online answering questions about their&#xD;
      disease diagnosis, testing, treatment, and symptoms. Participants will also be asked to take&#xD;
      the same survey 3, 6, and 9 months after completing the baseline survey. The data collected&#xD;
      from this study will be incorporated into the 23andMe Database and used to better understand&#xD;
      the underlying genetic and environmental factors that contribute to IPF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>IPF Symptom Progression Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Survey asking about disease diagnosis, testing, treatments, and symptom progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IPF Symptom Progression 3 month follow-up</measure>
    <time_frame>3 months post baseline</time_frame>
    <description>IPF Symptom Progression 3 month follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IPF Symptom Progression 6 month follow-up</measure>
    <time_frame>6 months post baseline</time_frame>
    <description>Survey asking about disease diagnosis, testing, treatments, and symptom progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IPF Symptom Progression 9 month follow-up</measure>
    <time_frame>9 months post baseline</time_frame>
    <description>Survey asking about disease diagnosis, testing, treatments, and symptom progression</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>IPF</arm_group_label>
    <description>Participants diagnosed with idiopathic pulmonary fibrosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>IPF</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will only include participants who meet the eligibility criteria as&#xD;
        described above. Participants in the study will be diagnosed with IPF or HPS.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have been diagnosed with IPF or Hermansky-Pudlak syndrome (HPS)&#xD;
&#xD;
          -  Are 18+ years old&#xD;
&#xD;
          -  Live in the US&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Have been diagnosed with sarcoidosis or hypersensitivity pneumonitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suyash Shringarpure</last_name>
    <role>Principal Investigator</role>
    <affiliation>23andMe, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suyash Shringarpure</last_name>
    <phone>1-650-933-9472</phone>
    <email>ipf-study@23andme.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>23andMe</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suyash Shringarpure</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.23andme.com/idiopathic-pulmonary-fibrosis/?utm_source=clinicaltrials</url>
    <description>Idiopathic Pulmonary Fibrosis Research Study landing page</description>
  </link>
  <link>
    <url>https://blog.23andme.com/research-communities/ipf/</url>
    <description>Blog post announcing the launch of the 23andMe IPF Research Study</description>
  </link>
  <link>
    <url>https://blog.23andme.com/23andme-research/insights-from-ipf-study/</url>
    <description>Blog post outlining insights from 23andMe customers who have IPF that are consented to research</description>
  </link>
  <link>
    <url>https://blog.23andme.com/23andme-research/living-with-pulmonary-fibrosis/</url>
    <description>Blog post interviewing Bill Vick, founder of PF Warriors, on living with IPF</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>idiopathic pulmonary fibrosis</keyword>
  <keyword>IPF</keyword>
  <keyword>pulmonary fibrosis</keyword>
  <keyword>lung diseases</keyword>
  <keyword>lung</keyword>
  <keyword>respiratory tract diseases</keyword>
  <keyword>rare</keyword>
  <keyword>rare diseases</keyword>
  <keyword>Hermansky-Pudlak syndrome</keyword>
  <keyword>HPS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

